3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
84
Neoplasm Metastasis
8
Neoplasms
6
Sarcoma
4
Squamous Cell Carcinoma of Head and Neck
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Untreated Operable Early Breast Cancer
1
Triple Negative Breast Neoplasms
1
Testicular Neoplasms
1
Teratoma
1
Somatostatinoma
1
Solid Tumors
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Squamous Cell Lung Carcinoma
1
Rectal Neoplasms
1
Interventions
Exercise
3
Paclitaxel
2
Cyclophosphamide
2
Control Groups
2
Capecitabine
2
Bupivacaine
2
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
palbociclib
1
iniparib
1
darolutamide
1
Yoga
1
Waiting Lists
1
Vitamin D
1
Thioctic Acid
1
Surveys and Questionnaires
1
Sodium Chloride
1
Ropivacaine
1
Radiofrequency Ablation
1
Neoadjuvant Therapy
1
Methotrexate
1
Metformin
1
Mastectomy, Segmental
1
Mastectomy
1
Letrozole
1
Electrochemotherapy
1
Educational Status
1
Drug Delivery Systems
1
Doxorubicin
1
Diet
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Breast Cancer Female
×
palbociclib
×
Clear all
NCT03065621
2023-04-19
NeoRHEA
Jules Bordet Institute
Phase 2
Completed
100 enrolled